Share buyback programme discontinued
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailCompany announcement no. 74
Spar Nord discontinues the current share buyback programme
In company announcement no. 10 of 12 February 2024, Spar Nord announced a share buyback programme of up to DKK 500 million. The share buyback programme was scheduled to end no later than on 31 January 2025.
With reference to company announcement no. 73 of 10 December 2024 regarding Nykredit’s announcement of all-cash voluntary takeover offer for Spar Nord Bank, the Bank’s Board of directors has decided to discontinue the current share buyback programme.
In last week the following transactions were made under the share buyback programme.
| Number of shares | Average purchase price (DKK) | Transaction value (DKK) | |
| Accumulated from last announcement | 3,206,446 | 408,459,537 | |
| 02 December 2024 | 16,200 | 140.35 | 2,273,670 |
| 03 December 2024 | 16,500 | 141.34 | 2,332,110 |
| 04 December 2024 | 16,900 | 136.99 | 2,315,131 |
| 05 December 2024 | 17,000 | 138.46 | 2,353,820 |
| 06 December 2024 | 17,200 | 139.49 | 2,399,228 |
| Total week 49 | 83,800 | 11,673,959 | |
| Total accumulated | 3,290,246 | 420,133,526 |
Following the above transactions. Spar Nord holds a total of 3,458,846 treasury shares equal to 2.94 % of the Bank’s share capital.
Please direct any questions regarding this release to Rune Brandt Børglum, CFO + 45 96 34 42 36.
Rune Brandt Børglum
CFO
Attachment
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- KFSH Extends Emergency Access Through Virtual Care and Specialist Coordination
- Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting
- Rooted in the River, Renewed with the Times: Insights from the 2026 Chishui River Forum
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Stock BuybackSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
